Reply To: Aprepitant usage and formulations

  • Stacy Wolf

    Member
    October 5, 2021 at 1:50 pm

    Hi Melissa,

    In the BMT setting, we use Aprepritant for conditioning regimens with high-emetogenic potential (if no drug-drug interactions), and also for patients with a prior history of significant CINV prior to coming to transplant. We only have the oral formulation at our institution (dosing below).

    Best,
    Stacy

    ——————————
    Stacy Wolf, RN,BMTCN,CPNP-AC,CPON
    Oakland Children’s Hospital
    Oakland, CA
    United States
    ——————————